TW201517904A - 兩性離子性軟式隱形眼鏡用眼科用組成物 - Google Patents
兩性離子性軟式隱形眼鏡用眼科用組成物 Download PDFInfo
- Publication number
- TW201517904A TW201517904A TW103118779A TW103118779A TW201517904A TW 201517904 A TW201517904 A TW 201517904A TW 103118779 A TW103118779 A TW 103118779A TW 103118779 A TW103118779 A TW 103118779A TW 201517904 A TW201517904 A TW 201517904A
- Authority
- TW
- Taiwan
- Prior art keywords
- scl
- pranoprofen
- ophthalmic composition
- salt
- zwitterionic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims abstract description 77
- 229960003101 pranoprofen Drugs 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 238000001179 sorption measurement Methods 0.000 claims abstract description 39
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000281 trometamol Drugs 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000003889 eye drop Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- -1 amine compound Chemical class 0.000 description 18
- 239000003814 drug Substances 0.000 description 12
- 239000012085 test solution Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- ZGMKMNLVGRQPMO-UHFFFAOYSA-N 2-naphthalen-1-yl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC2=CC=CC=C12 ZGMKMNLVGRQPMO-UHFFFAOYSA-N 0.000 description 1
- SVYBEBLNQGDRHF-UHFFFAOYSA-N 4-amino-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound S1C(CC)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 SVYBEBLNQGDRHF-UHFFFAOYSA-N 0.000 description 1
- OBNZPZAOTISUNM-UHFFFAOYSA-N 4-chloro-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound ClC1=CC(C(C=C1)(C)O)C OBNZPZAOTISUNM-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical group NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 1
- 229910052614 beryl Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940005636 dl- methylephedrine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical compound CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229940073475 lysozyme hydrochloride Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 229960003288 sulfaethidole Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 description 1
- 229960004257 sulfaguanidine Drugs 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明之目的為提供一種技術，其係使含有普拉洛芬及/或其鹽的兩性離子性軟式隱形眼鏡用眼科用組成物呈現澄清透明的外觀性狀，並且抑制普拉洛芬及/或其鹽吸附於兩性離子性軟式隱形眼鏡。
藉由在含有普拉洛芬及/或其鹽的兩性離子性軟式隱形眼鏡用眼科用組成物中摻合胺基丁三醇，並且將pH設定在5.5以上，可實現澄清透明的外觀性狀，而且可有效抑制普拉洛芬及/或其鹽吸附於兩性離子性軟式隱形眼鏡。
Description
本發明關於一種兩性離子性軟式隱形眼鏡用眼科用組成物，其係呈現澄清透明的外觀性狀，並可抑制普拉洛芬及/或其鹽吸附於兩性離子性軟式隱形眼鏡。另外，本發明還關於一種抑制普拉洛芬及/或其鹽吸附於兩性離子性軟式隱形眼鏡之方法。
普拉洛芬及/或其鹽具有抑制成為發炎或疼痛原因的前列腺素生合成的作用，在眼科領域被廣泛使用於眼睛充血或發癢等症狀的緩和、或眼瞼炎、結膜炎、包括上強膜炎的強膜炎、術後發炎、前眼部葡萄膜炎等的預防或治療的目的。另外，關於利用普拉洛芬及/或其鹽的眼科用組成物的製劑配方，也已經有了各種文獻報告。例如專利文獻1報告了一種含有普拉洛芬及/或其鹽與抗組織胺劑的局部用水性液劑，可發揮出優異的抗發炎作用及止癢作用。另外，專利文獻2報告了一種點眼劑，其係含有普拉洛芬及/或其鹽0.01~2.0w/v%與萘甲唑啉等的特定血管收縮劑0.0005~0.1w/v%，可有效地發揮除去或減輕外眼部充血
的作用。
另一方面，近年來開發出拋棄式或可長期連續配戴的軟式隱形眼鏡(以下也會有簡記為SCL的情形)，SCL的配戴者正在增加。另外，以往，SCL的材料大多採用呈現非離子性或陰離子性的材料，而近年來兩性離子性的材料也正在實用化以作為抑制淚液中的蛋白質、脂質、細胞斷片等堆積在SCL鏡片表面的材料。於是，為了提高兩性離子性SCL配戴者的便利性，正需要一種在配戴著兩性離子性SCL的狀態下可使用的點眼劑(兩性離子性SCL用點眼劑)。兩性離子性SCL用點眼劑必須調配成可發揮出所希望的藥效，而且不會對兩性離子性SCL造成不良影響。若兩性離子性SCL用點眼劑中的藥物吸附於SCL，則會造成鏡片變形、舒適感降低等，甚至還會有無法對眼睛黏膜發揮出所希望的藥理效果的情形，因此抑制藥物吸附於兩性離子性SCL，在兩性離子性SCL用點眼劑是特別重要的課題。
以往的SCL用點眼劑為了抑制藥物吸附於SCL，是採用選擇難以吸附於SCL的藥物、摻合了可抑制藥物吸附於SCL的成分等而成的製劑配方。例如在專利文獻3中報告了一種SCL用組成物，可抑制由具有2級或3級胺基的胺化合物所構成之鹼性藥物吸附在SCL，其製劑配方含有該鹼性藥物以及胺基酸、其鹽、酸性黏多糖、其鹽、或環糊精，並且將pH設定在3.5~4.8。
[專利文獻1]日本特開2002-193805號公報
[專利文獻2]國際公開第01/87304號
[專利文獻3]國際公開第2007/77783號
然而，專利文獻3是著眼於普拉洛芬及/或其鹽，關於其在兩性離子性SCL的吸附特性完全沒有作檢討。具有2級或3級胺基的胺化合物包括了各種藥物，而藥物在SCL的吸附特性也會因為胺基以外的構造而變動。甚至SCL的鏡片表面特性也會隨著離子性的有無、離子性的種類等而顯著不同，因此關於藥物在SCL的吸附特性，需要因應SCL的材料來作檢討。實際上，本發明人確認了兩性離子性SCL與非離子性SCL或陰離子性SCL相異，會有普拉洛芬及/或其鹽的吸附性極高這樣的特有課題(參照後述測試例1)。
此外，專利文獻3還依據必須將pH設定在4.8以下，然而本發明人確認了若將含有普拉洛芬及/或其鹽的SCL用眼科用組成物的pH調整在4.8以下的程度，則會有發生白濁而無法呈現可實用化的外觀性狀的問題(參照後述測試例2)。
以這樣的先前技術為背景，為了使含有普拉洛芬及/或其鹽的兩性離子性SCL用眼科用組成物實用化，需要充分考慮普拉洛芬及/或其鹽吸附於兩性離子性SCL的特性
而設計出呈現澄清透明的外觀性狀的製劑配方。
於是，本發明目的為提供一種技術，其係使含有普拉洛芬及/或其鹽的兩性離子性SCL用眼科用組成物呈現澄清透明的外觀性狀，並且抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL。
本發明人為了解決前述課題潛心檢討，結果發現藉由在含有普拉洛芬及/或其鹽的兩性離子性SCL用眼科用組成物中摻合胺基丁三醇，並且將pH設定在5.5以上，可實現澄清透明的外觀性狀，而且可有效抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL。本發明基於這樣的見解，進一步反覆檢討而完成。
亦即本發明提供以下所揭示態樣的發明。
1. 一種兩性離子性軟式隱形眼鏡用眼科用組成物，其特徵為：含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇，且pH為5.5以上。2. 如第1項所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其中，含有胺基丁三醇0.0001~5w/v%。
3. 如第1或2項所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其pH為5.5~9。
4. 如第1至3項中任一項所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其中，含有普拉洛芬及/或其藥學所容許的鹽0.001~0.5w/v%。
5. 如第1至4項中任一項所記載之兩性離子性軟式隱形眼
鏡用眼科用組成物，其為兩性離子性軟式隱形眼鏡用點眼劑。
6. 一種抑制普拉洛芬及/或其藥學所容許的鹽吸附於兩性離子性軟式隱形眼鏡之方法，其特徵為：在含有普拉洛芬及/或其藥學所容許的鹽的兩性離子性軟式隱形眼鏡用眼科用組成物中摻合胺基丁三醇，並且將pH調整至5.5以上。
7. 一種液劑用以製造兩性離子性軟式隱形眼鏡用眼科用組成物之用途，該液劑為含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇，且pH為5.5以上者。
8. 一種抑制普拉洛芬及/或其藥學所容許的鹽吸附於兩性離子性軟式隱形眼鏡之方法，其包括使含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇且pH為5.5以上的液劑與兩性離子性軟式隱形眼鏡接觸之步驟。
只要利用本發明之兩性離子性SCL用眼科用組成物，即可抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL，因此不會對兩性離子性SCL造成不良影響，而能夠有效地發揮普拉洛芬及/或其鹽的藥效。另外，在本發明之兩性離子性SCL用眼科用組成物中，藉由摻合作為pH調整劑使用的胺基丁三醇以及調整pH，可抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL，可任意地設定是否摻合其他藥理成分或添加劑，因此也有製劑配方上的限制少這樣的優點。
另外，利用本發明之兩性離子性SCL用眼科用組成物，藉由含有普拉洛芬及/或其鹽，同時將pH設定在4.8
以下的程度，即可抑制所產生的白濁，而能夠提供呈現澄清透明的外觀性狀的兩性離子性SCL用眼科用組成物。此外，在本說明書之中，「澄清透明」是指並未因為普拉洛芬及/或其鹽而發生白濁的狀態，其概念不限於無色澄清透明，還包括因為其他含有成分而呈色的有色澄清透明。
1.兩性離子性SCL用眼科用組成物本發明之兩性離子性SCL用眼科用組成物，其特徵為：含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇，且pH為5.5以上。以下針對本發明之兩性離子性SCL用眼科用組成物作詳細敘述。此外，在本說明書之中，「兩性離子性SCL用眼科用組成物」是表示被使用於眼科領域，而且在與兩性離子性SCL接觸狀態下使用的組成物。另外，在本說明書之中，各成分的濃度的單位「w/v%」代表質量相對於容量的百分率，與g/100mL同義。
本發明之兩性離子性SCL用眼科用組成物含有普拉洛芬及/或其鹽。普拉洛芬，亦被稱為α-甲基-5H-[1]苯并吡喃[2,3-b]吡啶-7-醋酸，在眼科領域是周知的具有消炎作用的化合物。
普拉洛芬之鹽在藥學所容許的限度內並不受特別限制，而可列舉例如鈉鹽、鉀鹽、鈣鹽、鎂鹽、鋁鹽等
的金屬鹽；三乙胺鹽、二乙胺鹽、嗎啉鹽、哌嗪鹽等的有機鹼鹽等。這些普拉洛芬之鹽可單獨使用一種，或可組合兩種以上來使用。
在本發明之兩性離子性SCL用眼科用組成物之中，可由普拉洛芬及其鹽之中選擇一種單獨使用，或可組合兩種以上來使用。普拉洛芬及其鹽之中，宜為例如普拉洛芬。
在本發明之兩性離子性SCL用眼科用組成物之中，普拉洛芬及/或其鹽的濃度可因應該兩性離子性SCL用眼科用組成物的用途等適當地設定，而可列舉例如0.001~0.5w/v%，宜為0.01~0.2w/v%、更佳為0.01~0.1w/v%。
本發明之兩性離子性SCL用眼科用組成物進一步含有胺基丁三醇。胺基丁三醇，亦被稱為三羥甲基胺基甲烷，在眼科領域是周知的可作為緩衝劑使用的化合物。
本發明之兩性離子性SCL用眼科用組成物之中，胺基丁三醇的濃度可列舉例如0.0001~5w/v%。尤其從更進一步有效抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL的觀點看來，胺基丁三醇的濃度宜為例如0.001~5w/v%、更佳為0.001~2w/v%。
本發明之兩性離子性SCL用眼科用組成物的pH設定在5.5以上。在本發明之兩性離子性SCL用眼科用組成物中，使前述普拉洛芬及/或其鹽與胺基丁三醇共存，並且將pH設定在這樣的範圍，藉此可抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL，同時可抑制白濁，而呈現澄清透明
的外觀性狀。
從更進一步有效抑制普拉洛芬及/或其鹽吸附於
兩性離子性SCL，同時具備澄清透明的外觀性狀的觀點看來，本發明之兩性離子性SCL用眼科用組成物的pH宜為例如5.5~9，較佳為6~8、更佳為6.5~8，特佳為6.5~7.5。
為了將本發明之兩性離子性SCL用眼科用組成
物的pH調整在前述範圍，只要在眼科用組成物中使用一般所使用的pH調整劑即可。pH調整劑可列舉例如氫氧化鈉、氫氧化鉀等的鹼；醋酸、檸檬酸、鹽酸、磷酸、酒石酸等的酸。這些pH調整劑可單獨使用一種，或可組合兩種以上來使用。
本發明之兩性離子性SCL用眼科用組成物中含
有可表現出緩衝作用的胺基丁三醇，因此即使不含其他緩衝劑也能夠具備緩衝能力，然而在不妨礙本發明效果的限度內，亦可因應必要含有其他緩衝劑。這種其他緩衝劑可列舉例如磷酸緩衝劑、硼酸緩衝劑、檸檬酸緩衝劑、酒石酸緩衝劑、醋酸緩衝劑、胺基酸等。這些緩衝劑可單獨使用一種，或可組合兩種以上來使用。
在本發明之兩性離子性SCL用眼科用組成物
中，除了前述成分以外，還可因應必要含有普拉洛芬及/或其鹽以外的藥理成分。這種藥理成分可列舉例如甘草酸二鉀、尿囊素、ε胺基己酸、溴芬酸、酮咯酸氨丁三醇、奈帕芬胺、小蘗鹼氯化物、硫酸小蘗鹼、薁磺酸鈉、硫酸鋅、乳酸鋅、溶菌酶鹽酸鹽等的消炎劑；氯菲安明馬來酸鹽、
二苯安明鹽酸鹽等的抗組織胺劑；色甘酸鈉、酮替芬富馬酸鹽、阿扎司特、氨來呫諾、吡嘧司特鉀、曲尼司特、異丁司特等的抗過敏劑；諾氟沙星、氧氟沙星、洛美沙星、左旋氧氟沙星、紫菌素、加替沙星等的抗菌劑；抗壞血酸、黃素腺嘌呤二核苷酸鈉、氰基鈷胺素、吡哆醇鹽酸鹽、生育酚醋酸酯、視黃醇醋酸酯、視黃醇棕櫚酸酯、泛醇、泛酸鈣、泛酸鈉等的維生素類；天門冬醯胺酸、牛磺酸、硫酸軟骨素鈉等的胺基酸類、新斯狄格明硫酸甲酯等的抗膽鹼酯酶劑；萘甲唑啉、四氫唑啉、腎上腺素、麻黃素、脫羥腎上腺素、dl-甲基麻黃素等的血管收縮劑；玻尿酸鈉等的角結膜上皮障礙治療藥；磺胺嘧啶、磺胺異噁唑、磺胺異嘧啶、磺胺二甲氧基嘧啶、磺胺甲氧基噠嗪、磺胺甲噁唑、磺胺乙基噻二唑、磺胺甲氧甲嘧啶、磺胺苯吡唑、磺胺胍、酞醯基磺胺噻唑、琥珀醯基磺胺噻唑等的磺胺劑等。此處所例示的化合物在藥學所容許的限度內可為鹽的形態，或可為其他鹽的形態。這些藥理成分可單獨使用一種，或可組合兩種以上來使用。
這些藥理成分的濃度可因應藥理成分的種類或兩性離子性SCL用眼科用組成物的用途等適當地設定。
另外，在本發明之兩性離子性SCL用眼科用組成物中，除了前述成分之外，還可因應必要含有等張化劑、溶解助劑、黏稠劑、螯合劑、清涼化劑、防腐劑、安定化劑、界面活性劑等的添加劑。
等張化劑可列舉山梨醇、葡萄糖、甘露醇等的糖
類；甘油、丙二醇等的多元醇類；氯化鈉等的鹽類；硼酸等。這些等張化劑可單獨使用一種，或可組合兩種以上來使用。
溶解助劑可列舉例如聚氧乙烯去水山梨醇單油
酸酯、聚氧乙烯硬化蓖麻油、泰洛沙伯、普朗尼克等的非離子性界面活性劑；甘油、聚乙二醇等的多元醇等。這些溶解助劑可單獨使用一種，或可組合兩種以上來使用。
黏稠劑可列舉例如聚乙烯基吡咯烷酮、聚乙二
醇、聚乙烯醇、羧乙烯基聚合物、黃原膠、硫酸軟骨素鈉、玻尿酸鈉等的水溶性高分子；羥丙基甲基纖維素、羥乙基纖維素、甲基纖維素、羥丙基纖維素、羥丙基甲基纖維素、羧甲基纖維素鈉等的纖維素類等。這些黏稠劑可單獨使用一種，或可組合兩種以上來使用。
螯合劑可列舉例如依地酸鹽、檸檬酸或其鹽等。這些螯合劑可單獨使用一種，或可組合兩種以上來使用。
清涼化劑可列舉例如l-薄荷醇、龍腦、樟腦、桉樹油等。這些清涼化劑可單獨使用一種，或可組合兩種以上來使用。
防腐劑可列舉例如山梨酸或其鹽、安息香酸或其鹽、對羥安息香酸甲酯、對羥安息香酸乙酯、對羥安息香酸丙基、氯丁醇、氯己定葡萄糖酸鹽、硼酸、去氫醋酸或其鹽、苯紮氯銨、苄索氯銨、苄醇、氯化鋅、對氯間二甲酚、氯甲酚、苯乙醇、泊利氯銨、硫汞撒、二丁基羥基甲苯等。這些防腐劑可單獨使用一種，或可組合兩種以上來
使用。
安定化劑可列舉例如聚乙烯基吡咯烷酮、亞硫酸鹽、單乙醇胺、甘油、丙二醇、環糊精、聚葡萄糖、抗壞血酸、依地酸鹽、牛磺酸、生育酚、二丁基羥基甲苯等。這些安定化劑可單獨使用一種，或可組合兩種以上來使用。
界面活性劑可列舉例如泰洛沙伯、聚氧乙烯硬化蓖麻油、聚氧乙烯聚氧丙烯嵌段共聚物、聚氧乙烯去水山梨醇脂肪酸酯、辛基酚聚醚等的非離子性界面活性劑；烷基二胺乙基甘胺酸、月桂基二甲基胺基醋酸甜菜鹼等的兩性界面活性劑；烷基硫酸鹽、N-醯基牛磺酸鹽、聚氧乙烯烷醚磷酸鹽、聚氧乙烯烷醚硫酸鹽等的陰離子界面活性劑；烷基吡啶鎓鹽、烷基胺鹽等的陽離子界面活性劑等。這些界面活性劑可單獨使用一種，或可組合兩種以上來使用。
這些添加劑的濃度可因應添加劑的種類或兩性離子性SCL用眼科用組成物的用途等適當地設定。
本發明之兩性離子性SCL用眼科用組成物的製劑形態只要含有水作為基劑即可，例如可為水溶液狀、乳液狀等的任一者，而宜為例如水溶液狀。
本發明之兩性離子性SCL用眼科用組成物，只要因應其用途，依據周知的調製法來製造即可，例如可採用第16改正日本藥典製劑總則所記載的方法來製造。
本發明之兩性離子性SCL用眼科用組成物，可使用作為在配戴著兩性離子性SCL時可使用的點眼劑(兩性離
子性SCL用點眼劑)；在配戴著兩性離子性SCL時可使用的洗眼劑(兩性離子性SCL用洗眼劑)；兩性離子性SCL用配戴液、兩性離子性SCL用多效保養液、兩性離子性SCL用洗淨液、兩性離子性SCL用保存液等的隱形眼鏡保養用品等。該等之中，宜為例如兩性離子性SCL用點眼劑、兩性離子性SCL用洗眼劑，更佳為兩性離子性SCL用點眼劑。
作為本發明的適用對象的兩性離子性SCL，是指以含有具有陽離子性基的單體與具有陰離子性基的單體以作為離子性單體的聚合物為構成材料的SCL。兩性離子性SCL具體而言，可列舉以含有四級銨鹽等的陽離子性基與羧基、磺酸基、磷酸基等的陰離子性基的聚合物為構成材料的SCL，其材料或製法被記載於例如日本特開平10-197831號公報等。
另外，作為本發明之適用對象的兩性離子性SCL可為高含水率或低含水率之任一者，而宜為例如高含水率者，亦即美國食品醫藥品局(FDA)分類為群組IV者(離子性單體1莫耳%以上，含水率50%以上)。
2.抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL的方法(1)另外，本發明提供一種抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL的方法，其特徵為：在含有普拉洛芬及/或其藥學所容許的鹽的兩性離子性SCL用眼科用組成物中摻合胺基丁三醇，並且將pH調整在5.5以上。該吸附抑制方法在對於兩性離子性SCL用眼科用組成物賦予抑制普拉洛芬及/或
其鹽吸附於兩性離子性SCL的作用上是有用的。
在本發明的吸附抑制方法之中，所使用的普拉洛
芬及/或其藥學所容許的鹽的種類或濃度、胺基丁三醇的濃度、兩性離子性SCL用眼科用組成物的pH、摻合至兩性離子性SCL用眼科用組成物的藥理成分或添加劑的種類、兩性離子性SCL用眼科用組成物的製劑形態或用途、作為適用對象的兩性離子性SCL的種類等，如前述「1.兩性離子性SCL用眼科用組成物」之欄所記載。
3.抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL的方法(2)另外，本發明提供一種抑制普拉洛芬及/或其鹽吸附於兩性離子性SCL之方法，其係包括含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇且pH為5.5以上的液劑，與兩性離子性SCL接觸之步驟。
在本發明的吸附抑制方法中，所使用的普拉洛芬及/或其藥學所容許的鹽的種類或濃度、胺基丁三醇的濃度、液劑的pH、摻合至液劑的藥理成分或添加劑的種類、液劑的製劑形態或用途、作為適用對象的兩性離子性SCL的種類等，如前述「1.兩性離子性SCL用眼科用組成物」之欄所記載。另外，在本發明的吸附抑制方法之中，使前述液劑與兩性離子性SCL接觸之方法只要因應該液劑的用途適當地設定即可。例如在前述液劑為點眼劑的情況，只要將前述液劑滴在配戴著兩性離子性SCL的眼睛即可。
以下列舉實施例，對本發明作具體說明，然而本
發明完全不受該等所限定。此外，在以下的測試例之中，普拉洛芬是使用API Corporation股份有限公司製的產品，胺基丁三醇是使用日本藥典外的醫藥品規格的胺基丁三醇(UE-E)(關東化學股份有限公司製)或特級三(羥甲基)胺基甲烷(Nacalai Tesque股份有限公司製)。
測試例1藉由常法混合表1所示的各成分而調製出測試液。藉由觀察所得到的各測試液的外觀，並且測定濁度(在660nm的吸光度)，以評估白濁的有無。
另外，將各測試液2mL裝入樣品瓶，將一枚SCL浸漬於其中，在25℃下振盪2小時以上。另外，將各測試液2mL裝入樣品瓶，在沒有浸漬SCL的狀態並且在25℃下振盪2小時以上。振盪後，以液相層析測定各測試液中的普拉洛芬含量，依據下式計算出普拉洛芬吸附於SCL吸附量。此外還可確認若在測試液中浸漬SCL的條件下振盪，則在2小時以內，普拉洛芬吸附於SCL達到平衡狀態，因此只要將振盪時間設定在2小時以上，則對於普拉洛芬吸附於SCL的吸附量的測定值沒有影響。
[數1]普拉洛芬吸附在一枚SCL上的吸附量(μg)=(CC-CT)×V
CC：並未浸漬SCL的測試液中的普拉洛芬含量(μg/mL)
CT：浸漬SCL的測試液中的普拉洛芬含量(μg/mL)
V：測試所使用的測試液的量(mL)
此外，在此測試中使用下述4種SCL，求得普拉洛芬在各SCL的吸附量。
鏡片1：群組IV、商品名「SEED 1dayPure」(註冊商標)Seed公司股份有限公司製)、兩性離子性、鏡片材料：甲基丙烯酸2-羥乙酯(HEMA)、含4級銨基的甲基丙烯酸酯系化合物、含羧基的甲基丙烯酸酯系化合物、甲基丙烯酸甲酯(MMA)、乙二醇二甲基丙烯酸酯(EGDMA)
鏡片2：群組IV、商品名「SEED 1dayPure UP(加強濕潤)」(註冊商標)Seed公司股份有限公司製)、兩性離子性、鏡片材料：甲基丙烯酸2-羥乙酯(HEMA)、含有4級銨基的甲基丙烯酸酯系化合物、含羧基的甲基丙烯酸酯系化合物、甲基丙烯酸甲酯(MMA)、乙二醇二甲基丙烯酸酯(EGDMA)
鏡片3：群組IV、商品名「1-DayAcuvue(註冊商標)」(Johnson & Johnson medical公司製)、陰離子性、USAN名：etafilcon A
鏡片4：聚矽氧水凝膠隱形眼鏡、群組I、商品名AIR OPTIX 2week(註冊商標)」(CIBA Vision公司製)、USAN名：lotrafilcon B
將所得到的結果揭示於表1。由此結果可確認在pH7.5的情況，任一測試液皆為無色澄清透明，呈現良好的外觀性狀。另外，判明了在不含胺基丁三醇的測試液(比較例1)的情況中，普拉洛芬幾乎沒有吸附在陰離子性SCL及非離子性的SCL，相對於此，明顯觀察到普拉洛芬的吸附在兩性離子性SCL，普拉洛芬具有容易吸附在兩性離子性SCL
這樣的特有性質。相對於此，含有普拉洛芬以及胺基丁三醇，且pH7.5的測試液(實施例1~5)可抑制普拉洛芬吸附於兩性離子性SCL。
表中各配方成分的摻合量的單位為「w/v%」。
n.m.(1)表示未測定。
測試例2藉由常法混合表2所示的各成分而調製出測試液。藉由觀察所得到的各測試液的外觀，並且測定濁度(在660nm的吸光度)，以評估白濁的有無。另外，以與前述測試例1同樣的方法對於所得到的各測試液測定普拉洛芬吸附於兩性離子性SCL的吸附量。
將所得到的結果揭示於表2。由此結果可確認，若pH在4.5以下，則觀察到測試液呈白濁，外觀性狀惡化，然而在pH為5.5以上的情況，會呈現澄清透明的外觀性狀。另外，隨著pH變高，還觀察到普拉洛芬吸附於兩性離子性SCL的吸附量有增加的傾向，然而含有胺基丁三醇的測試液可有效抑制普拉洛芬吸附於兩性離子性SCL。以上的結果確認了藉由含有普拉洛芬以及胺基丁三醇，並且將pH設定在5.5以上，可呈現澄清透明的外觀性狀，並且可抑制普拉洛芬吸附於兩性離子性SCL。
表中各配方成分的摻合量的單位為「w/v%」。
n.m.(1)表示未測定。
n.m.(2)是因為白濁而未測定。
測試例3藉由常法混合表3所示的各成分而調製出測試液。藉由觀察所得到的各測試液的外觀，並且測定濁度(在660nm的吸光度)，以評估白濁的有無。另外，對於所得到的各測試液，與前述測試例1同樣的方法，測定普拉洛芬吸附於兩性離子性SCL的吸附量。此外，在此測試中，兩性離子性SCL採用前述測試例1所使用的鏡片2(群組IV、兩性離子性)來進行測試。
將所得到的結果揭示於表3。由表3明顯可知，使用胺基丁三醇以外的緩衝劑成分並無法充分降低普拉洛芬吸附於兩性離子性SCL的吸附量。亦即，由此測試結果判明了抑制普拉洛芬吸附於兩性離子性SCL，是藉由選擇胺基丁三醇作為所含的成分，並且將pH設定在5.5以上所觀察到的特有效果。
表中各配方成分的摻合量的單位為「w/v%」。
#1 HEPES是指2-[4-(2-羥乙基)哌嗪-1-基]乙磺酸的簡稱。
Claims (8)
- 一種兩性離子性軟式隱形眼鏡用眼科用組成物，其特徵為：含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇，且pH為5.5以上。
- 如請求項1所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其中，含有胺基丁三醇0.0001~5w/v%。
- 如請求項1或2所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其pH為5.5~9。
- 如請求項1至3中任一項所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其中，含有普拉洛芬及/或其藥學所容許的鹽0.001~0.5w/v%。
- 如請求項1至4中任一項所記載之兩性離子性軟式隱形眼鏡用眼科用組成物，其為兩性離子性軟式隱形眼鏡用點眼劑。
- 一種抑制普拉洛芬及/或其藥學所容許的鹽吸附於兩性離子性軟式隱形眼鏡之方法，其特徵為：在含有普拉洛芬及/或其藥學所容許的鹽的兩性離子性軟式隱形眼鏡用眼科用組成物中摻合胺基丁三醇，並且將pH調整至5.5以上。
- 一種液劑用以製造兩性離子性軟式隱形眼鏡用眼科用組成物之用途，該液劑為含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇，且pH為5.5以上者。
- 一種抑制普拉洛芬及/或其藥學所容許的鹽吸附於兩性 離子性軟式隱形眼鏡之方法，其包括使含有普拉洛芬及/或其藥學所容許的鹽與胺基丁三醇且pH為5.5以上的液劑與兩性離子性軟式隱形眼鏡接觸之步驟。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013114372 | 2013-05-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201517904A true TW201517904A (zh) | 2015-05-16 |
| TWI623314B TWI623314B (zh) | 2018-05-11 |
Family
ID=51988767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103118779A TWI623314B (zh) | 2013-05-30 | 2014-05-29 | 兩性離子性軟式隱形眼鏡用眼科用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP6401699B2 (zh) |
| CN (1) | CN105392481B (zh) |
| HK (1) | HK1217901A1 (zh) |
| RU (1) | RU2669570C2 (zh) |
| TW (1) | TWI623314B (zh) |
| WO (1) | WO2014192738A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI630931B (zh) * | 2017-04-10 | 2018-08-01 | 明基材料股份有限公司 | 眼用鏡片及其製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3170619B2 (ja) * | 1995-04-20 | 2001-05-28 | 参天製薬株式会社 | 有機アミンを配合したプラノプロフェン点眼液 |
| JP4919666B2 (ja) * | 2005-01-26 | 2012-04-18 | ロート製薬株式会社 | プラノプロフェン含有組成物 |
| JP2007008928A (ja) * | 2005-06-01 | 2007-01-18 | Rohto Pharmaceut Co Ltd | アシタザノラスト含有水性組成物 |
| US8435965B2 (en) * | 2005-12-27 | 2013-05-07 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| JP6009141B2 (ja) * | 2009-10-09 | 2016-10-19 | ロート製薬株式会社 | 水性組成物 |
| JP5909152B2 (ja) * | 2011-06-02 | 2016-04-26 | ロート製薬株式会社 | トラニラストを含有する水性組成物 |
-
2014
- 2014-05-27 WO PCT/JP2014/063960 patent/WO2014192738A1/ja active Application Filing
- 2014-05-27 JP JP2015519868A patent/JP6401699B2/ja not_active Expired - Fee Related
- 2014-05-27 RU RU2015154023A patent/RU2669570C2/ru not_active IP Right Cessation
- 2014-05-27 CN CN201480029909.8A patent/CN105392481B/zh not_active Expired - Fee Related
- 2014-05-29 TW TW103118779A patent/TWI623314B/zh not_active IP Right Cessation
-
2016
- 2016-05-23 HK HK16105849.4A patent/HK1217901A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105392481B (zh) | 2018-10-12 |
| JP6401699B2 (ja) | 2018-10-10 |
| RU2015154023A3 (zh) | 2018-03-14 |
| HK1217901A1 (zh) | 2017-01-27 |
| JPWO2014192738A1 (ja) | 2017-02-23 |
| WO2014192738A1 (ja) | 2014-12-04 |
| CN105392481A (zh) | 2016-03-09 |
| RU2669570C2 (ru) | 2018-10-12 |
| RU2015154023A (ru) | 2017-07-06 |
| TWI623314B (zh) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020007356A (ja) | アトロピン含有水性組成物 | |
| WO2014204791A1 (en) | Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations | |
| JP5650947B2 (ja) | イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| TW201818922A (zh) | 水性液劑 | |
| JP6449774B2 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 | |
| JP5834427B2 (ja) | ソフトコンタクトレンズへの吸着抑制方法 | |
| JP2003128552A (ja) | 粘膜適用組成物 | |
| TW201513858A (zh) | 軟式隱形眼鏡用眼科用組成物 | |
| TWI623314B (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 | |
| JP6449773B2 (ja) | 陰イオン性ソフトコンタクトレンズ用眼科用組成物 | |
| JP2003128585A (ja) | 外用組成物 | |
| JP2012006962A (ja) | 眼科用組成物 | |
| JP2020075918A (ja) | 角膜上皮創傷治癒促進用の眼科用組成物 | |
| TWI626060B (zh) | 兩性離子性軟式隱形眼鏡用眼科用組成物 | |
| KR102444571B1 (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
| JP2020109121A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| KR20160138179A (ko) | 수성 의약 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |